Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB 1 R) Receptor with Reduced Lipophilicity.

In the present report, we describe the synthesis and structure-activity relationships of novel "four-arm" dihydropyrazoline compounds designed as peripherally restricted antagonists of cannabinoid-1 receptor (CB 1 R). A series of racemic 3,4-diarylpyrazolines were synthesized and evaluated initially in CB 1 receptor binding assays. The novel compounds, designed to limit brain penetrance and decreased lipophilicity, showed high affinity for CB 1 R and potent in vitro CB 1 R antagonist activities. Promising compounds with potent CB 1 R activity were evaluated in tissue distribution studies. Compounds 6a , 6f , and 7c showed limited brain penetrance attesting to its peripheral restriction. The 4 S -enantiomer of these compounds further showed a stereoselective affinity for the CB 1 receptor and behaved as inverse agonists. In vivo studies on food intake and body weight reduction in diet-induced obese (DIO) mice showed that these compounds could serve as potential leads for the development of selective CB 1 R antagonists with improved potency and peripheral restriction.